CORT (Corcept Therapeutics) Float Percentage Of Total Shares Outstanding: 77.46% (As of Jun. 27, 2026)


CORT Corcept Therapeutics Inc CORT
82 GF Score
Price $87.32
GF Value $61.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Float Percentage Of Total Shares Outstanding?

Corcept Therapeutics CORT +3.03% 82 Float Percentage Of Total Shares Outstanding is 77.46% as of Jun. 27, 2026. GuruFocus rates CORT with a GF Score™ of 82/100 and a GF Value™ of $61.67 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Corcept Therapeutics's float shares is 83.16 Mil. Corcept Therapeutics's total shares outstanding is 107.35 Mil. Corcept Therapeutics's float percentage of total shares outstanding is 77.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Corcept Therapeutics's Insider Ownership is 7.37%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Corcept Therapeutics's Institutional Ownership is 83.01%.

CORT
82GF Score
Corcept Therapeutics Inc CORT
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Corcept Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=83.16/107.35
=77.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 77.46% mean?
Corcept Therapeutics (CORT) has a Float Percentage Of Total Shares Outstanding of 77.46% as of Jun. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Corcept Therapeutics' current Float Percentage Of Total Shares Outstanding is 77.46%. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Float Percentage Of Total Shares Outstanding compare to PCVX and IBRX?
Corcept Therapeutics' Float Percentage Of Total Shares Outstanding of 77.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Float Percentage Of Total Shares Outstanding is 77.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.67, compared to a current price of $87.32 — trading 41.6% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 77.46%. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Float Percentage Of Total Shares Outstanding is 77.46% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $87.32 is trading 41.6% above its estimated GF Value™ of $61.67. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • Float Percentage Of Total Shares Outstanding: 77.46%
  • GF Value™: $61.67 vs. price of $87.32 (41.6% above fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score

Get the complete analysis for CORT

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.32
Price
$61.67
GF Value